TY - CONF
T1 - Long-term efficacy and safety data for dupilumab in a phase 3, Open-Label Extension Trial (LIBERTY AD PED-OLE) in patients aged >= 6 to < 12 years with moderate-to-severe atopic dermatitis (AD)
JO - JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
PY - 2021/01/01
AU - Cork MJ
AU - Thaci D
AU - Eichenfield L
AU - Arkwright PD
AU - Bastian M
AU - Chen Z
AU - Delevry D
AU - O'Malley JT
AU - Bansal A
ED -
VL - 19
SP - 14
EP - 14
Y2 - 2025/07/20
ER -